This temporal and spatial/regional regulation of ECM stiffness by invading tumor cells may be responsible for the lack of correlations between LOXL3, clinicopathological parameters, and breast cancer subtypes in our TMA cohorts. This evidence concerns the gene LOXL3 and breast cancer.